Show simple item record

dc.contributor.authorMedina-Lara, A
dc.contributor.authorKigozi, J
dc.contributor.authorAmurwon, J
dc.contributor.authorMuchabaiwa, L
dc.contributor.authorNyanzi Wakaholi, B
dc.contributor.authorMujica-Mota, Ruben
dc.contributor.authorWalker, AS
dc.contributor.authorKasirye, R
dc.contributor.authorSsali, F
dc.contributor.authorReid, A
dc.contributor.authorGrosskurth, H
dc.contributor.authorBabiker, AG
dc.contributor.authorKityo, C
dc.contributor.authorKatabira, E
dc.contributor.authorMunderi, P
dc.contributor.authorMugyenyi, P
dc.contributor.authorHakim, J
dc.contributor.authorDarbyshire, J
dc.contributor.authorGibb, DM
dc.contributor.authorGilks, CF
dc.contributor.authorDART Trial Team
dc.date.accessioned2013-07-04T09:38:05Z
dc.date.issued2012-04-24
dc.description.abstractDespite funding constraints for treatment programmes in Africa, the costs and economic consequences of routine laboratory monitoring for efficacy and toxicity of antiretroviral therapy (ART) have rarely been evaluated.en_GB
dc.identifier.citationVol. 7, Issue 4, article e33672en_GB
dc.identifier.doi10.1371/journal.pone.0033672
dc.identifier.urihttp://hdl.handle.net/10871/11524
dc.language.isoenen_GB
dc.publisherPublic Library of Scienceen_GB
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/22545079en_GB
dc.titleCost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabween_GB
dc.typeArticleen_GB
dc.date.available2013-07-04T09:38:05Z
exeter.place-of-publicationUnited States
dc.descriptionCopyright: © 2012 Medina Lara et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.en_GB
dc.identifier.journalPLoS Oneen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record